Director：Dr. ZENG Su, Professor
Tel：86-571-88208405
Email：zengsu@zju.edu.cn
The Institute of drug metabolism and pharmaceutical analysis of Zhejiang University was established in 2015. Its history can be traced back to the course of toxic analytical chemistry established by Professor Huang Mingju, founder and pioneer of modern toxic analytical chemistry in China, in 1924. With the efforts of several generations, it has developed into a comprehensive institute with interdisciplinary intersection. The discipline of pharmaceutical analysis was approved as a master program by the Academic Degrees Committee of the State Council in 1984, a doctoral program in 2000, and a national key (cultivation) discipline and a key discipline of Zhejiang Province in 2007. In 2010, it was approved as the national Eleventh Five Year Plan preclinical pharmacokinetics technology platform. In 2012, TCM analysis was approved as a key discipline of the State Administration of traditional Chinese medicine and a key discipline of traditional Chinese medicine in Zhejiang Province.
Research interests: 1. Computer aided drug design and target discovery: artificial intelligence and computer-aided drug design, target discovery, virtual screening, ADMET and drug-likeness prediction, drug functional omics, database construction; 2. Precision medicine: new drug research and biomarker discovery based on gene polymorphism and somatic mutation, and precision medical technology research based on antibody coupled drugs; 3. Drug metabolism: function and regulation mechanism of drug transporters and metabolic enzymes, epigenetic regulation mechanism and detection, construction and application of humanized drug metabolism model, DM / PK; 4. Pharmaceutical analysis: molecular analysis of drug active components and drug effects, new technologies and methods for target and biomarker analysis, stability and quality analysis of biological drugs, new structural characterization of biological drugs and industrial preparation technology.
Faculty: Currently 10 professors/researchers, 7 associate professors/researchers and 1 lecturer in total, with national and provincial awards/titles.
Grants and Publications: 10+ key projects of NSFC, major national science and technology projects, national key R & D plans, and more than 30 general projects and youth projects of NSFC. 400+ SCI papers including Cell, Sci Transl Med, Nat Commun, Adv Mater, WIREs Comput Mol Sci, PNAS, Nucleic Acids Res, J Am Chem Soc, J Med Chem, Drug Metab Dispo, Adv Drug Delivery Rev, and Trends Pharmacol Sci. 60+ domestic and international invention patents, software copyrights and 1 clinical approvals of new drugs.
Education: Currently 50 doctoral students and 66 master students in total, with awards and honors including national scholarship, Chu Kochen scholarship, Liu Changxiao Talent Award, excellent doctoral student award, and the excellent dissertation of Zhejiang Province. Graduates employment including Harvard University, Cambridge University, the University of Michigan, Peking University, Zhejiang University, 1st hospital of Zhejiang Province, Huawei Technology Co., Ltd., Hengrui Pharmaceuticals Co., Ltd. and other well-known enterprises and institutions all over the world. Current positions: professors / researchers in domestic universities, Dean of the School of pharmacy, Dean Assistant and deputy director of the Research Institute, vice president of the third-class hospital, chief pharmacist, assistant professor of world-class university, manager of R & D company of international multinational pharmaceutical enterprises, senior executives of pharmaceutical enterprises, etc.
International cooperation: served as deputy editor in chief, editorial board member and guest editor of 30 international journals for 36 times, undertook a number of international cooperation projects, and organized high-level international conferences, including the academic conference of the international society of drug metabolism.
Social services: completed more than 80 enterprise service projects and helped enterprises obtain 9 approvals for new drug clinical trials.
